Clinical Practice Guidelines for assessment and management of iron deficiency

Kidney International

Volumn 74, Issue SUPPL.110, 2008, Pages

  Madore, Francois ^a   White, Colin T ^b   Foley, Rob N ^c   Barrett, Brendan J ^d   Moist, Louise M ^e   Klarenbach, Scott W ^f   Culleton, Bruce F ^g   Tonelli, Marcello ^f   Manns, Braden J ^g  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ANTIANEMIC AGENT; BIOLOGICAL MARKER;

ADVERSE DRUG REACTION; ANAPHYLAXIS; CHILL; CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION REACTION; DRUG SAFETY; DRUG USE; DYSPNEA; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INFECTION; INFLAMMATION; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON OVERLOAD; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRANSFERRIN BLOOD LEVEL; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; IRON DEFICIENCY ANEMIA; MEDICAL RESEARCH; METABOLISM; RENAL REPLACEMENT THERAPY;

ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; FERRITINS; HEMATINICS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TRANSFERRIN;

EID: 53449089917     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.269     Document Type: Article

References (40)

1. Van Wyck DB, Roppolo M, Martinez CO et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68: 2846-2856.
2. Aggarwal HK, Nand N, Singh S et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 2003; 51: 170-174.
3. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001; 16: 967-974.
4. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005; 100: c55-c62.
5. DeVita MV, Frumkin D, Mittal S et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003; 60: 335-340.
6. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538.
7. Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 1999; 34: 508-513.
8. Kalantar-Zadeh K, Hoffken B, Wunsch H et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26: 292-299.
9. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984.
10. Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 2002; 57: 136-141.
11. Guyader D, Jacquelinet C, Moirand R et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115: 929-936.
12. Morrison ED, Brandhagen DJ, Phatak PD et al. Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627-633.
13. Adams PC, Deugnier Y, Moirand R et al. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997; 25: 162-166.
14. Crawford DH, Jazwinska EC, Cullen LM et al. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998; 114: 1003-1008.
15. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321-1328.
16. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46.
17. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699.
18. Fudin R, Jaichenko J, Shostak A et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998; 79: 299-305.
19. Markowitz GS, Kahn GA, Feingold RE et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997; 48: 34-40.
20. Lenga I, Lok C, Marticorena R et al. Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol 2007; 2: 688-693.
21. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15(Suppl 2): S93-S98.
22. Beshara S, Lundqvist H, Sundin J et al. Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anemic patients: a study using positron emission tomography. Br J Haematol 1999; 104: 296-302.
23. Unknown. Ferrlecit Product Package Insert. Watson Pharmaceuticals Inc.: Corona, CA 2001.
24. Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood 1969; 34: 357-375.
25. Michael B, Coyne DW, Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830-1839.
26. Aronoff GR, Bennett WM, Blumenthal S et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004; 66: 1193-1198.
27. Blaustein DA, Schwenk MH, Chattopadhyay J et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int Suppl 2003: S72-S77.
28. Charytan C, Schwenk MH, Al-Saloum MM et al. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract 2004; 96: c63-c66.
29. McCarthy JT, Regnier CE, Loebertmann CL et al. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products. Am J Nephrol 2000; 20: 455-462.
30. Walters BA, Van Wyck DB. Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients. Nephrol Dial Transplant 2005; 20: 1438-1442.
31. Fletes R, Lazarus JM, Gage J et al. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37: 743-749.
32. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-1731.
33. Fishbane S, Ungureanu VD, Maesaka JK et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-534.
34. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33: 464-470.
35. Bailie GR, Clark JA, Lane CE et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443-1449.
36. Novey HS, Pahl M, Haydik I et al. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy 1994; 72: 224-228.
37. Agarwal R, Vasavada N, Sachs NG et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289.
38. Boelaert JR, Daneels RF, Schurgers ML et al. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990; 5: 130-134.
39. Hoen B, Kessler M, Hestin D et al. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995; 10: 377-381.
40. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis 1997; 25: 888-895.